Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

High Expression of ANXA2 Pseudogene ANXA2P2 Promotes an Aggressive Phenotype in Hepatocellular Carcinoma.

Wang QS, Shi LL, Sun F, Zhang YF, Chen RW, Yang SL, Hu JL.

Dis Markers. 2019 Feb 10;2019:9267046. doi: 10.1155/2019/9267046. eCollection 2019.

2.

Pseudogenes of annexin A2, novel prognosis biomarkers for diffuse gliomas.

Li S, Zou H, Shao YY, Mei Y, Cheng Y, Hu DL, Tan ZR, Zhou HH.

Oncotarget. 2017 Oct 31;8(63):106962-106975. doi: 10.18632/oncotarget.22197. eCollection 2017 Dec 5.

3.

Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma.

Zhang HJ, Yao DF, Yao M, Huang H, Wu W, Yan MJ, Yan XD, Chen J.

World J Gastroenterol. 2012 Nov 7;18(41):5897-904. doi: 10.3748/wjg.v18.i41.5897.

4.

Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families.

He XX, Shi LL, Qiu MJ, Li QT, Wang MM, Xiong ZF, Yang SL.

Biochem Biophys Res Commun. 2018 Oct 12;504(4):878-884. doi: 10.1016/j.bbrc.2018.08.203. Epub 2018 Sep 12.

PMID:
30219235
5.

MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence.

Liu M, Hu Q, Tu M, Wang X, Yang Z, Yang G, Luo R.

J Exp Clin Cancer Res. 2018 Jan 22;37(1):10. doi: 10.1186/s13046-017-0669-z.

6.

A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.

Zhu P, Jin J, Liao Y, Li J, Yu XZ, Liao W, He S.

Oncotarget. 2015 Dec 1;6(38):41383-97. doi: 10.18632/oncotarget.5510.

7.

Upregulated TRIO expression correlates with a malignant phenotype in human hepatocellular carcinoma.

Wang B, Fang J, Qu L, Cao Z, Zhou J, Deng B.

Tumour Biol. 2015 Sep;36(9):6901-8. doi: 10.1007/s13277-015-3377-3. Epub 2015 Apr 8.

PMID:
25851347
8.

Regulator of Calcineurin 1 Gene Isoform 4, Down-regulated in Hepatocellular Carcinoma, Prevents Proliferation, Migration, and Invasive Activity of Cancer Cells and Metastasis of Orthotopic Tumors by Inhibiting Nuclear Translocation of NFAT1.

Jin H, Wang C, Jin G, Ruan H, Gu D, Wei L, Wang H, Wang N, Arunachalam E, Zhang Y, Deng X, Yang C, Xiong Y, Feng H, Yao M, Fang J, Gu J, Cong W, Qin W.

Gastroenterology. 2017 Sep;153(3):799-811.e33. doi: 10.1053/j.gastro.2017.05.045. Epub 2017 Jun 2.

PMID:
28583823
9.

Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.

Zhang MH, Niu H, Li Z, Huo RT, Wang JM, Liu J.

Cancer Biomark. 2018;23(1):33-43. doi: 10.3233/CBM-181277.

PMID:
29991125
10.

Annexin A2 silencing inhibits invasion, migration, and tumorigenic potential of hepatoma cells.

Zhang HJ, Yao DF, Yao M, Huang H, Wang L, Yan MJ, Yan XD, Gu X, Wu W, Lu SL.

World J Gastroenterol. 2013 Jun 28;19(24):3792-801. doi: 10.3748/wjg.v19.i24.3792.

11.

Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression.

Tu K, Dou C, Zheng X, Li C, Yang W, Yao Y, Liu Q.

BMC Cancer. 2014 Dec 12;14:938. doi: 10.1186/1471-2407-14-938.

12.

Hint1 suppresses migration and invasion of hepatocellular carcinoma cells in vitro by modulating girdin activity.

Wu XS, Bao TH, Ke Y, Sun DY, Shi ZT, Tang HR, Wang L.

Tumour Biol. 2016 Nov;37(11):14711-14719. Epub 2016 Sep 14.

PMID:
27623945
13.

MiR-892a Promotes Hepatocellular Carcinoma Cells Proliferation and Invasion Through Targeting CD226.

Jia B, Tan L, Jin Z, Jiao Y, Fu Y, Liu Y.

J Cell Biochem. 2017 Jun;118(6):1489-1496. doi: 10.1002/jcb.25808. Epub 2016 Dec 29.

PMID:
27883251
14.

A Preliminary Investigation of PVT1 on the Effect and Mechanisms of Hepatocellular Carcinoma: Evidence from Clinical Data, a Meta-Analysis of 840 Cases, and In Vivo Validation.

Zhang Y, Wen DY, Zhang R, Huang JC, Lin P, Ren FH, Wang X, He Y, Yang H, Chen G, Luo DZ.

Cell Physiol Biochem. 2018;47(6):2216-2232. doi: 10.1159/000491534. Epub 2018 Jul 5.

15.

Long non-coding RNA SNHG20 predicts a poor prognosis for HCC and promotes cell invasion by regulating the epithelial-to-mesenchymal transition.

Liu J, Lu C, Xiao M, Jiang F, Qu L, Ni R.

Biomed Pharmacother. 2017 May;89:857-863. doi: 10.1016/j.biopha.2017.01.011. Epub 2017 Mar 6.

PMID:
28282787
16.

Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients.

Chen D, Chen Y, Yan Y, Pan J, Xing W, Li Q, Zeng W.

BMC Cancer. 2017 Aug 18;17(1):553. doi: 10.1186/s12885-017-3541-9.

17.

Overexpression of RALY promotes migration and predicts poor prognosis in hepatocellular carcinoma.

Zhu Z, Zhang Y, Huang C, Tang Y, Sun C, Ju W, He X.

Cancer Manag Res. 2018 Nov 9;10:5559-5572. doi: 10.2147/CMAR.S182996. eCollection 2018.

18.

miR-663a inhibits tumor growth and invasion by regulating TGF-β1 in hepatocellular carcinoma.

Zhang C, Chen B, Jiao A, Li F, Sun N, Zhang G, Zhang J.

BMC Cancer. 2018 Nov 28;18(1):1179. doi: 10.1186/s12885-018-5016-z.

19.

Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.

Tong M, Che N, Zhou L, Luk ST, Kau PW, Chai S, Ngan ES, Lo CM, Man K, Ding J, Lee TK, Ma S.

J Hepatol. 2018 Oct;69(4):826-839. doi: 10.1016/j.jhep.2018.05.034. Epub 2018 Jun 7.

PMID:
29885413
20.

Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.

Lu LL, Sun J, Lai JJ, Jiang Y, Bai LH, Zhang LD.

World J Gastroenterol. 2015 Jun 7;21(21):6649-59. doi: 10.3748/wjg.v21.i21.6649.

Supplemental Content

Support Center